Home » China CRO Attracts $30 Million U.S. Investment
China CRO Attracts $30 Million U.S. Investment
China’s second largest contract research organisation (CRO) ShangPharma has attracted $30m (€21m) from U.S. private investment firm TPG as the Asian pharma market continues to simmer.
Outsourcing-Pharma
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May